Researchers commented that this might be due to potential masking effects of salmeterol in airway inflammation in asthmatic population with LRS, i.e., by simple BDRs beta-2 agonists
relieve symptoms without arresting the principal inflammation causing COPD.
are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease and another respiratory distress status.
Currently, for acute severe asthma, guideline recommendations suggest repeated use of inhaled short-acting beta-2 agonists
, up to 10 puffs repeated every 10 to 20 minutes, or repeated nebulised dosing.
Previous studies showed that treatment with beta-2 agonists
, in particular salbutamol, might increase the incidence of cardiac arrhythmia at high doses in asthmatics (1, 2,8).
One approach is to treat this patient with a long-acting beta-2 agonist
such as salmeterol or formoterol around the clock.
The beta-2 agonist
use was reduced by 95%, and the corticosteroid inhaler was reduced by 92%.
Overall, the results indicate that daily use of an inhaled short-acting beta-2 agonist
was associated [odds ratio (OR) = 1.5, p [less than].05] with an asthma-related hospitalization when compared to the control group.
The report recommends that "regularly scheduled, short-acting inhaled beta-2 agonist
treatment should be kept to a minimum." Beta-2 agonists
offer relief but don't control symptoms, affect peak expiratory flow rates, or alter airway hyperresponsiveness.
The report compared the use of the newer anti-inflammatory drugs with the more conventional asthma drugs, such as theophylline and the newer bronchodilators known as beta-2 agonists
. Many physicians now think the anti-inflammatory medications are more appropriate in many instances.
* Inhaled short-acting beta-2 agonists
and anticholinergic bronchodilators have positive effects.
These patients generally maintain asthma control with daily use of a combination of inhaled corticosteroid and long-acting beta-2 agonist
, and having a short-acting beta-2 agonist
available for quick relief.
'Wada has conducted several studies on salbutamol and continues to conduct studies on beta-2 agonists
. We believe the current threshold is solid considering the scientific literature published on salbutamol over the past 20 years.